B-lymphocyte tolerance and effector function in immunity and autoimmunity

被引:0
|
作者
Wasif N. Khan
Jacqueline A. Wright
Eden Kleiman
Justin C. Boucher
Iris Castro
Emily S. Clark
机构
[1] University of Miami Miller School of Medicine,Department of Microbiology and Immunology
来源
Immunologic Research | 2013年 / 57卷
关键词
Transitional B cells; Marginal zone B cells; Tolerance; Autoimmunity; B-cell antigen receptor; B-cell-activating factor receptor; Toll-like receptor; Apoptosis; Bruton’s tyrosine kinase; BH3-only protein Bim; Signaling cross talk;
D O I
暂无
中图分类号
学科分类号
摘要
B-lymphocytes are integral to host defense against microbial pathogens and are associated with many autoimmune diseases. The B-cell receptor implements B-cell self-tolerance based on the antigen specificity, and B-cell-activating factor receptor (BAFF-R) imposes homeostatic control. While shaping the repertoire, the immune tolerance process also culls mature B cells into distinct populations. The activation response of B cells is tailored to the type of pathogen attack and is facilitated by T-cell help via CD40/CD40L interaction and/or innate cell help via toll-like receptors in conjunction with BAFF receptors and ligands. Activated effector B cells not only produce antibodies, but also produce a variety of cytokines to enhance and suppress the immune response. Not surprisingly, B cells play multiple roles in both humoral and cellular immune responses during infection and autoimmune pathogenesis. Here, we discuss how gene expression and signaling networks regulate peripheral B-cell tolerance, B-cell effector functions and emerging therapies targeting B-cell signaling in autoimmune diseases.
引用
收藏
页码:335 / 353
页数:18
相关论文
共 50 条
  • [41] What is the CLL B-lymphocyte?
    Dighiero, G
    Kipps, T
    Schroeder, HW
    Chiorazzi, N
    Stevenson, F
    Silberstein, LE
    CaligarisCappio, F
    Ferrarini, M
    LEUKEMIA & LYMPHOMA, 1996, 22 : 13 - 39
  • [42] THE B-LYMPHOCYTE AS AN IMMUNOTHERAPEUTIC TARGET
    FEARON, DT
    QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1995, 88 (03): : 149 - 153
  • [43] T Lymphocyte trafficking in immunity and autoimmunity
    Sallusto, Frederica
    CYTOKINE, 2009, 48 (1-2) : 45 - 45
  • [44] B-LYMPHOCYTE HETEROGENEITY - DEVELOPMENT AND CHARACTERIZATION OF AN ALLOANTISERUM WHICH DISTINGUISHES B-LYMPHOCYTE DIFFERENTIATION ALLOANTIGENS
    AHMED, A
    SCHER, I
    SHARROW, SO
    SMITH, AH
    PAUL, WE
    SACHS, DH
    SELL, KW
    JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 145 (01): : 101 - 110
  • [45] Learning from panel boards: T-lymphocyte and B-lymphocyte self-tolerance game
    Eckert, GU
    Da Rosa, ACM
    Busnello, RG
    Melchior, R
    Masiero, PR
    Scroferneker, ML
    MEDICAL TEACHER, 2004, 26 (06) : 521 - 524
  • [46] B-LYMPHOCYTE FUNCTION IS ALTERED BY PROTEASE ACTIVATED RECEPTOR-1
    McKelvey, K.
    Jackson, C.
    Xue, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 792 - 792
  • [47] Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
    Pescovitz, Mark D.
    Greenbaum, Carla J.
    Krause-Steinrauf, Heidi
    Becker, Dorothy J.
    Gitelman, Stephen E.
    Goland, Robin
    Gottlieb, Peter A.
    Marks, Jennifer B.
    McGee, Paula F.
    Moran, Antoinette M.
    Raskin, Philip
    Rodriguez, Henry
    Schatz, Desmond A.
    Wherrett, Diane
    Wilson, Darrell M.
    Lachin, John M.
    Skyler, Jay S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (22): : 2143 - 2152
  • [48] Combined standard and novel immunosuppressive substances affect B-lymphocyte function
    Matz, Mareen
    Lehnert, Martin
    Lorkowski, Christine
    Fabritius, Katharina
    Weber, Ulrike A.
    Mashreghi, Mir-Farzin
    Neumayer, Hans-H.
    Budde, Klemens
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 15 (04) : 718 - 725
  • [49] EFFECT OF ANTIALKALINE PHOSPHATASE MONOCLONAL-ANTIBODY ON B-LYMPHOCYTE FUNCTION
    MARTY, LM
    FELDBUSH, TL
    IMMUNOLOGY LETTERS, 1993, 38 (02) : 87 - 95
  • [50] IMMUNOSUPPRESSIVE PROPERTY OF BROMOCRIPTINE ON HUMAN B-LYMPHOCYTE FUNCTION IN-VITRO
    MORKAWA, K
    OSEKO, F
    MORIKAWA, S
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1993, 93 (02): : 200 - 205